Teva Pharmaceuticals USA Inc. and Cephalon Inc. sued the U.S. Food and Drug Administration in Washington federal court Tuesday seeking to bar the agency from robbing Teva of the marketing exclusivity period they say it earned through patent certifications for its generic version of Cephalon's blockbuster sleep disorder drug Provigil.
Stay ahead of the curve
In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.
Direct access to case information and documents.
All significant new filings across U.S. federal district courts, updated hourly on business days.
Full-text searches on all patent complaints in federal courts.